A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
Latest Information Update: 15 Feb 2024
At a glance
- Drugs RSLV 132 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Resolve Therapeutics
- 12 Feb 2024 According to a Resolve Therapeutics Media Release, results from this trial published in Lupus Science & Medicine.
- 12 Feb 2024 Results presented in a Resolve Therapeutics Media Release.
- 09 Dec 2020 Results published in the Resolve Therapeutics Media Release.